Trials / Conditions / Refractory Hepatocellular Carcinoma
Refractory Hepatocellular Carcinoma
6 registered clinical trials studyying Refractory Hepatocellular Carcinoma — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Suspended | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing He NCT06968195 | Roswell Park Cancer Institute | Phase 1 |
| Not Yet Recruiting | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure NCT07075419 | West China Hospital | Phase 1 / Phase 2 |
| Recruiting | Ligufalimab and Cadonilimab in Advanced Liver Cancers NCT06789848 | University of Texas Southwestern Medical Center | Phase 2 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Terminated | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer NCT04777708 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |